FDA Approves ImageChecker Computer System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ImageChecker uses a laser beam to convert the mammographic image into a digital signal. The signal is processed in a high-speed computer to identify suspicious areas, which are then highlighted with markers on a video display of the mammographic image. The radiologist, who has already reviewed the mammo-gram in the conventional manner, then looks at the suspicious areas highlighted by ImageChecker and reviews those same areas on the original mammogram to see if any escaped notice, and, if so, whether they require further evaluation.

FDA’s approval of ImageChecker was based on data from clinical studies and the recommendation of the Radiological Devices Panel of FDA’s Medical Devices Advisory Committee.

Recent Videos
6 experts are featured in this series.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
6 experts are featured in this series.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content